① The “Study on the Myocardial Protective Effects of China Tongxinluo in the Treatment of Acute Myocardial Infarction (CTS-AMI)” led by Professor Yang Yuejin of Fuwai Hospital of the Chinese Academy of Medical Sciences published original research results in “JAMA”. This is the first time that an evidence-based original study of a proprietary Chinese medicine has appeared in a top international journal. ② Tongxinuo can significantly reduce the risk of 30-day Macces events by about 36% and the risk of cardiogenic death by 30%.
Financial News Agency, November 16 (Reporter Zhang Liangde) For the first time, original evidence-based research on proprietary Chinese medicines appeared in top international medical journals. Yiling Pharmaceutical (002603.SZ) announced tonight that the “Study on the Myocardial Protective Effects of Chinese Tongxinluo in the Treatment of Acute Myocardial Infarction (CTS-AMI)” led by Professor Yang Yuejin of Fuwai Hospital of the Chinese Academy of Medical Sciences has published original research results in “JAMA”, one of the top four international medical journals. Research results show that Tongxinluo can reduce the risk of death from acute myocardial infarction by 30%.
This morning, the results of the “Clinical Efficacy of China Tongxin Network in Treating Acute Myocardial Infarction - CTS-AMI Randomized Clinical Study” project were officially announced at the “National Key Research and Development Program 'Context Theory Guidance System Interventions in Cardiovascular Incident Chain Research' results conference” held at the Beijing National Convention Center. Academicians Gao Runlin, Zhang Boli, Zhang Yun, Wu Yiling, and Han Yaling of the Chinese Academy of Engineering, Shen Jianzhong, Deputy Director of the China Biotechnology Development Center, and Professor Eric D. Peterson (Eric D. Peterson) of the Southwestern Medical Center at the University of Texas, USA, and tens of thousands of medical experts and scholars attended the conference online and offline.
The picture shows Yang Yuejin
Professor Gao Runlin, an Academician of the Chinese Academy of Engineering and Fuwai Hospital of the Chinese Academy of Medical Sciences, said in an interview with the Financial News Agency and other media, “Through this evidence-based medicine study, it has been proved that Tongxinluo is indeed effective in treating myocardial infarctions.” “The publication of this study in “JAMA” shows that it has been recognized by the international academic community.”
Yang Yuejin explained at the conference that out of 3,3797 randomly assigned patients, 3,777 patients were included in the main analysis, including 1,889 in the Tongxin Group and 1,888 in the placebo group. The main end point of the study was the 30-day major adverse cardiovascular event (MacCEs). The study results showed that Tongxinluo can significantly reduce the risk of 30-day mAccES events by about 36% and the risk of cardiogenic death by 30%.
In an interview with reporters, Yang Yuejin said that this should be the first article in history to be published in the top international medical journals of proprietary Chinese medicines to treat myocardial infarction. At the same time, this study also found a perfect combination of traditional Chinese and Western medicine, which is evidence-based medicine.
Professor Wu Yiling, an Academician of the Chinese Academy of Engineering and founder of Yiling Pharmaceutical, said at the conference that in addition to Tongxinluo capsules, Yiling Pharmaceutical's main products such as Shensong Yangxin capsules, Qiluqiangxin capsules, and Jinlida capsules have all carried out evidence-based medical research.
Professor Huang Congxin of the People's Hospital of Wuhan University and Professor Li Xinli of the First Affiliated Hospital of Nanjing Medical University gave academic reports on the “Clinical Study on the Prognosis of Patients with Atrial Fibrillation via Radiofrequency Atrial Fibrillation” and “Evaluation Study on the Treatment of Complicated Chronic Heart Failure with Qiyi Qiangxin Capsule” respectively. Studies have shown that the combination of standardized treatment with Qizi Qiangxin reduced the risk of major complex end events by 22% compared to the control group. Sansong Yangxin capsules can reduce the risk of recurrence of internal atrial fibrillation by about 40% 1 year after radiofrequency ablation surgery.
According to data, Eling Pharmaceutical achieved sales revenue of 4.178 billion yuan in 2022, accounting for 33.33% of the company's total revenue; cardiovascular products achieved sales revenue of 4.178 billion yuan in 2022, accounting for 33.33% of the company's total revenue; in the first half of 2023, cardiovascular products achieved sales revenue of 2,511 billion yuan, accounting for 36.98% of the company's total operating income, an increase of 10.42% over 2,274 billion yuan in the same period last year.
Some participating experts told the Financial Association and many other media reporters, “The patients in this study all came from China, and did not include patients from overseas. Therefore, it is estimated that there will be no change in international medication guidelines, but it may have an impact on domestic medication guidelines.”